Speakers
The 2022 List of Faculty – Work in progress
Pravin Chaturvedi
Pravin Chaturvedi, PhD, is CEO of OCEANYX Pharmaceuticals and Chair of the Scientific Advisory Board for NAPO Pharmaceuticals, Woburn MA, USA. Dr Chaturvedi is the Summit Honorary Chair. He is widely recognized one of MA’s key opinion leaders in Biotechnology. He has developed over 7 new treatments in CNS, GI and viral diseases over his career.
Yvette Cleland
Yvette Cleland is CEO of CPL Life Sciences, a global staffing firm specializing in exceptional talent within Biopharma. Having come from the pharmaceutical sector herself she leads with an innate understanding of talent needs, shortages & addressing the dilemma’s. Yvette has been recognized since 2018 by Staffing Industry Analysts (SIA) as one of the top 50 most powerful women in staffing globally. In recent years her work was included in a UK Parliamentary Review
Marc De Garidel
Marc de Garidel is the CEO of Cincor Pharma since July 1, 2021, a private biotechnology company dedicated to developing a novel treatment against hypertension. Prior to joining CinCor, Mr. de Garidel served as CEO of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company that was acquired by Novo Nordisk in August 2020 for $2.1 billion.
Vanessa Elharrar
Vanessa Elharrar, M.D., MPH, is Vice President Vaccines Strategy Lead within PPD Biotech. She has been focused exclusively on COVID-19 clinical development since the beginning of the pandemic. She has 14+ years experience in infectious disease clinical research and NIH leadership.
Jessica Foley
Jessica Foley, RAC: Regulatory Affairs Certified, Principal, Gaia Regulatory Sciences LLC. She is a regulatory expert with 17 years of experience in rare and common disease indications, including pulmonary, immunology, neurology, inflammation, and oncology. She provides strategic advice, submissions support, and due diligence services for small molecule, biologic, and cell and gene therapy development programs and has directed the preparation of global health authority interactions.
Marc B. Garnick
Marc B. Garnick, M.D., is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and the Beth Israel Deaconess Medical Center, where he also directs the Hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has just completed a 10 year tenure as a special governmental advisory member of multiple FDA panels and advisory committees.
Naji Gehchan
Naji Gehchan, MD is Global Development Leader Oncology at Eli Lilly leading the development of an oncology asset from early to late phase. Prior to this role, he led Northeast USA sales teams in diabetes bringing life-changing medicines to Healthcare Providers helping patients with diabetes.
Shahin Gharakhanian
Shahin Gharakhanian, MD, DPH, specializes in Drug & Vaccine Clinical Development & Medical Affairs, based in the Cambridge Innovation Center. He has extensive track record in Pharmaceutical Medicine, Executive Leadership & Management. Dr Gharakhanian has led or managed projects for 12 different companies, ten brands in different geographies (Asia, Europe, USA) including four NDA/MAA/launches, most recently a 2011 “blockbuster” in the US.
Silvia Helou
Silvia Helou, MD, Executive Consultant & Founder, HConsulting LLC. Silvia has extensive drug development experience in major therapeutic areas including anti-infectives, dermatology, oncology/hematology, and immunology/biologics. She previously held various senior positions at Novartis, Schering-Plough and Scynexis in clinical development.
Frederic Jallat
Dr. Frédéric Jallat is currently Professor, Academic Director of the Advanced Master in Biopharmaceutical Management (MsM – Paris & London), Associate Research Fellow at ESCP Business School, and an affiliated Professor at Sciences Po. Paris. He is currently working, as Co-Academic Director of the Advanced Management Program in Life Sciences and Health (APiL), on the development of a major initiative for entrepreneurship and innovation together with Institut Pasteur.
Daniel Kuritzkes
Daniel R. Kuritzkes, MD, Harvard Medical School, he is the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.
Cécile Le Camus
Cecile Le Camus, MD, Global Head of Hemophilia for RBD (Rare Blood Disorders), Medical Affairs Group, Sanofi-Genzyme, Cambridge MA, USA. Formerly she was head of the US Medical Affairs at Vertex Pharmaceuticals, Boston MA.
Corinne Le Goff
Corinne Le Goff, Pharm.D., MBA, President & CEO Celsion Corporation, Lawrenceville, N.J./Boston MA. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas including oncology, vaccines, immunology, CNS and cardio-metabolism.
Thomas Lingelbach
Thomas Lingelbach, President & Chief Executive Officer, Valneva. He was CEO of Intercell and founding CEO of Valneva. He is an established vaccine industry leader with breadth of experience. Prior to Valneva, Thomas had senior & executive management roles with Intercell, Novartis and Chiron.
Anup Madan
Dr. Anup Madan, PhD, serves as Director of Biomarkers for PPD® Laboratories, part of Thermo Fisher Scientific. He has more than 20 years of experience using high throughput genomics and system approaches to better understand disease etiology and identify biomarkers for P4 medicine. He has contributed to more than 60 peer reviewed publications in prestigious journals including Science and Nature.
Brian Malkin
Brian Malkin, Partner, McDermott Will & Emery, counsels pharmaceutical and biologic clients on Food and Drug Administration (FDA) regulatory matters and intellectual property (IP) law, with an emphasis on patent litigation.
Mac Martirossian
Mac Martirossian, CPA, Managing Director, MThree Advisory, Atlanta GA. Mac is a senior level General Management executive with a successful history of maximizing organizational effectiveness, profit and cash flow, both domestically and internationally.
Regis Mulot
Regis Mulot is the Executive Vice President, Chief Human Resources Officer at Ipsen, a global biopharmaceutical group with over 5,700 employees in 40 countries. He has more than 30 years of multicultural HR experience, both at global and local levels. He joined Ipsen from Staples Inc. where he was Executive Vice President, Chief Human Resources Officer.
Karine Rossignol
Karine ROSSIGNOL, PharmD, is the Chief Executive Officer of Smart Immune SAS, a T cell medicine clinical stage biotechnology company that she co-founded in 2017 with Pr. Marina Cavazzana and Dr. Isabelle André in July 2017. Karine has more than 25 years management experience in both industry and biomedical research institutes.
Delphine Saragoussi
Delphine Saragoussi, MD, MScPH
Executive Director, Real-World Evidence, Strategic and Scientific Affairs at EVIDERA (PPD) Greater Paris Metropolitan Region. Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity.
Ann M. Stowe
Ann M. Stowe is an Associate Professor with Tenure in the Dept. of Neurology at the University of Kentucky (Lexington, KY, USA), Co-Founder and equity holder of Cerelux, LLC. She use preclinical studies to investigate the mechanisms by which adaptive immune responses affect post-stroke plasticity. Her clinical studies into the role of neuroinflammation during brain injury and repair has expanded beyond the field of ischemic stroke.
